Vanessa Kiyomi Ota

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7242896/publications.pdf

Version: 2024-02-01

76 papers	2,438 citations	304602 22 h-index	254106 43 g-index
89 all docs	89 docs citations	89 times ranked	3300 citing authors

#	Article	IF	Citations
1	The impact of neighborhood context on telomere length: A systematic review. Health and Place, 2022, 74, 102746.	1.5	7
2	Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia. Molecular Neurobiology, 2022, 59, 3170-3182.	1.9	4
3	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	13.7	929
4	Is treatment-resistant schizophrenia associated with distinct neurobiological callosal connectivity abnormalities?. CNS Spectrums, 2021, 26, 545-549.	0.7	4
5	Association between polymorphism in gene related to the dopamine circuit and motivations for drinking in patients with alcohol use disorder. Psychiatry Research, 2021, 295, 113563.	1.7	5
6	Obsessive-Compulsive Symptoms, Polygenic Risk Score, and Thalamic Development in Children From the Brazilian High-Risk Cohort for Mental Conditions (BHRCS). Frontiers in Psychiatry, 2021, 12, 673595.	1.3	1
7	BDNF in antipsychotic naive first episode psychosis: Effects of risperidone and the immune-inflammatory response system. Journal of Psychiatric Research, 2021, 141, 206-213.	1.5	12
8	Aging biological markers in a cohort of antipsychotic-naÃ¯ve first-episode psychosis patients. Psychoneuroendocrinology, 2021, 132, 105350.	1.3	7
9	Polyenvironmental and polygenic risk scores and the emergence of psychotic experiences in adolescents. Journal of Psychiatric Research, 2021, 142, 384-388.	1.5	1
10	Impact of duration of untreated psychosis in shortâ€term response to treatment and outcome in antipsychotic naÃ¯ve firstâ€episode psychosis. Microbial Biotechnology, 2020, 14, 677-683.	0.9	7
11	Are serum brain-derived neurotrophic factor concentrations related to brain structure and psychopathology in late childhood and early adolescence?. CNS Spectrums, 2020, 25, 790-796.	0.7	1
12	LINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort. Epigenomics, 2020, 12, 1041-1051.	1.0	7
13	A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?. International Journal of Neuropsychopharmacology, 2020, 23, 721-730.	1.0	6
14	A systematic review on the effects of social discrimination on telomere length. Psychoneuroendocrinology, 2020, 120, 104766.	1.3	25
15	Gene expression changes associated with trajectories of psychopathology in a longitudinal cohort of children and adolescents. Translational Psychiatry, 2020, 10, 99.	2.4	3
16	Blood gene expression changes after Risperidone treatment in an antipsychotic-naÃ¯ve cohort of first episode of psychosis patients. Schizophrenia Research, 2020, 220, 285-286.	1.1	3
17	Implications of an admixed Brazilian population in schizophrenia polygenic risk score. Schizophrenia Research, 2019, 204, 404-406.	1.1	6
18	F136TOBACCO AND ALCOHOL CONSUMPTION IS ASSOCIATED WITH DNA METHYLATION CHANGES IN CHILDREN AND ADOLESCENTS AT HIGH RISK OF PSYCHIATRIC DISORDERS. European Neuropsychopharmacology, 2019, 29, S1184.	0.3	0

#	Article	IF	Citations
19	Detecting multiple differentially methylated CpG sites and regions related to dimensional psychopathology in youths. Clinical Epigenetics, 2019, 11, 146.	1.8	13
20	Effects of the interaction between genetic factors and maltreatment on child and adolescent psychiatric disorders. Psychiatry Research, 2019, 273, 575-577.	1.7	0
21	LEUKOCYTE TELOMERE LENGTH ANALYSIS IN CHILDREN AND ADOLESCENTS AT RISK OF DEVELOPING MENTAL DISORDERS. European Neuropsychopharmacology, 2019, 29, S931-S932.	0.3	0
22	GENOME-WIDE DNA METHYLATION ANALYSIS IN A LONGITUDINAL COHORT OF ANTIPSYCHOTIC-NAIVE FIRST EPISODE OF PSYCHOSIS PATIENTS. European Neuropsychopharmacology, 2019, 29, S1007-S1008.	0.3	0
23	EVALUATION OF GENE EXPRESSION IN EARLY SUBSTANCE ABUSE. European Neuropsychopharmacology, 2019, 29, S884-S885.	0.3	0
24	Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia. Schizophrenia Research, 2019, 208, 202-208.	1.1	14
25	DGCR2 influences cortical thickness through a mechanism independent of schizophrenia pathogenesis. Psychiatry Research, 2019, 274, 391-394.	1.7	4
26	Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages. NPJ Schizophrenia, 2019, 5, 5.	2.0	16
27	Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis. European Neuropsychopharmacology, 2019, 29, 416-431.	0.3	67
28	Accessing Gene Expression in Treatment-Resistant Schizophrenia. Molecular Neurobiology, 2018, 55, 7000-7008.	1.9	23
29	Effects of the brain-derived neurotropic factor variant Val66Met on cortical structure in late childhood and early adolescence. Journal of Psychiatric Research, 2018, 98, 51-58.	1.5	11
30	Leukocyte telomere length variation in different stages of schizophrenia. Journal of Psychiatric Research, 2018, 96, 218-223.	1.5	25
31	Effect of male-specific childhood trauma on telomere length. Journal of Psychiatric Research, 2018, 107, 104-109.	1.5	11
32	Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder. Communications Biology, 2018, 1, 163.	2.0	17
33	Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. Translational Psychiatry, 2018, 8, 174.	2.4	49
34	Gene expression in blood of children and adolescents: Mediation between childhood maltreatment and major depressive disorder. Journal of Psychiatric Research, 2017, 92, 24-30.	1.5	25
35	Singleâ€nucleotide polymorphisms in genes related to the hypothalamicâ€pituitaryâ€adrenal axis as risk factors for posttraumatic stress disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 671-682.	1.1	19
36	Implication of LRRC4C and DPP6 in neurodevelopmental disorders. American Journal of Medical Genetics, Part A, 2017, 173, 395-406.	0.7	40

#	Article	IF	Citations
37	Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls. Revista Brasileira De Psiquiatria, 2017, 39, 302-308.	0.9	26
38	The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data. Revista Brasileira De Psiquiatria, 2017, 39, 160-171.	0.9	15
39	Hair cortisol in drug-naÃ¯ve first-episode individuals with psychosis. Revista Brasileira De Psiquiatria, 2016, 38, 11-16.	0.9	15
40	Vascular loops in the anterior inferior cerebellar artery, as identified by magnetic resonance imaging, and their relationship with otologic symptoms. Radiologia Brasileira, 2016, 49, 300-304.	0.3	20
41	Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis. Translational Psychiatry, 2016, 6, e908-e908.	2.4	26
42	Genome-wide investigation of schizophrenia associated plasma Ndel1 enzyme activity. Schizophrenia Research, 2016, 172, 60-67.	1.1	10
43	Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic NaÃ¯ve First Episode Psychosis. Molecular Neurobiology, 2016, 53, 5701-5709.	1.9	59
44	A molecular model for neurodevelopmental disorders. Translational Psychiatry, 2015, 5, e565-e565.	2.4	38
45	Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis. International Journal of Neuropsychopharmacology, 2015, 18, pyu042-pyu042.	1.0	77
46	Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naÃ¯ve first episode psychosis. Schizophrenia Research, 2015, 166, 225-230.	1.1	34
47	Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls. World Journal of Biological Psychiatry, 2015, 16, 441-446.	1.3	14
48	Oxidative stress in drug naÃ¯ve first episode psychosis and antioxidant effects of risperidone. Journal of Psychiatric Research, 2015, 68, 210-216.	1.5	51
49	Effects of depression on the cytokine profile in drug naÃ¯ve first-episode psychosis. Schizophrenia Research, 2015, 164, 53-58.	1.1	48
50	ACE I/D genotype-related increase in ACE plasma activity is a better predictor for schizophrenia diagnosis than the genotype alone. Schizophrenia Research, 2015, 164, 109-114.	1.1	19
51	Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR). Psychiatry Research, 2015, 229, 690-694.	1.7	11
52	High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World Journal of Biological Psychiatry, 2015, 16, 422-429.	1.3	69
53	Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naÃ¯ve patients with first-episode psychosis. European Neuropsychopharmacology, 2015, 25, 2416-2425.	0.3	23
54	PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia. PLoS ONE, 2014, 9, e87686.	1.1	14

#	Article	IF	Citations
55	Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiology and Behavior, 2014, 129, 194-198.	1.0	49
56	Early life adversity, genomic plasticity, and psychopathology. Lancet Psychiatry,the, 2014, 1, 461-466.	3.7	118
57	Changes in gene expression and methylation in the blood of patients with first-episode psychosis. Schizophrenia Research, 2014, 159, 358-364.	1.1	35
58	BisQC: an operational pipeline for multiplexed bisulfite sequencing. BMC Genomics, 2014, 15, 290.	1.2	10
59	Association of APOE, GCPII and MMP9 polymorphisms with common diseases and lipid levels in an older adult/elderly cohort. Gene, 2014, 535, 370-375.	1.0	14
60	Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR). Schizophrenia Research, 2014, 157, 163-168.	1.1	22
61	Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: A follow-up study in antipsychotic-naÃ¯ve patients with first-episode psychosis. Journal of Psychiatric Research, 2014, 56, 130-136.	1.5	13
62	Expression profile of neurotransmitter receptor and regulatory genes in the prefrontal cortex of spontaneously hypertensive rats: Relevance to neuropsychiatric disorders. Psychiatry Research, 2014, 219, 674-679.	1.7	11
63	Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naÃ¯ve first-episode psychosis patients before and after antipsychotic treatment. Psychiatry Research, 2013, 210, 1290-1292.	1.7	11
64	Polymorphisms in schizophrenia candidate gene UFD1L may contribute to cognitive deficits. Psychiatry Research, 2013, 209, 110-113.	1.7	5
65	Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia. Schizophrenia Research, 2013, 148, 81-86.	1.1	55
66	ZDHHC8 gene may play a role in cortical volumes of patients with schizophrenia. Schizophrenia Research, 2013, 145, 33-35.	1.1	18
67	Candidate genes for schizophrenia in a mixed Brazilian population using pooled DNA. Psychiatry Research, 2013, 208, 201-202.	1.7	3
68	Is there an association between cortical thickness, age of onset, and duration of illness in schizophrenia?. CNS Spectrums, 2013, 18, 315-321.	0.7	17
69	Short Communication Association of APOA1 and APOA5 polymorphisms and haplotypes with lipid parameters in a Brazilian elderly cohort. Genetics and Molecular Research, 2013, 12, 3495-3499.	0.3	11
70	DRD1 rs4532 polymorphism: A potential pharmacogenomic marker for treatment response to antipsychotic drugs. Schizophrenia Research, 2012, 142, 206-208.	1.1	34
71	Linkage Replication for Chromosomal Region 13q32 in Schizophrenia: Evidence from a Brazilian Pilot Study on Early Onset Schizophrenia Families. PLoS ONE, 2012, 7, e52262.	1.1	5
72	Assessment of 22q11.2 copy number variations in a sample of Brazilian schizophrenia patients. Schizophrenia Research, 2011, 132, 99-100.	1.1	12

#	Article	IF	Citations
73	PPARÎ± polymorphisms as risk factors for dyslipidemia in a Brazilian population. Molecular Genetics and Metabolism, 2011, 102, 189-193.	0.5	10
74	APOA4 Polymorphism as a Risk Factor for Unfavorable Lipid Serum Profile and Depression: A Cross-Sectional Study. Journal of Investigative Medicine, 2011, 59, 966-970.	0.7	25
75	APOA1/A5Variants and Haplotypes as a Risk Factor for Obesity and Better Lipid Profiles in a Brazilian Elderly Cohort. Lipids, 2010, 45, 511-517.	0.7	18
76	The UFD1L rs5992403 polymorphism is associated with age at onset of schizophrenia. Journal of Psychiatric Research, 2010, 44, 1113-1115.	1.5	10